Merus N.V. announced on December 7, 2024, interim clinical data from its ongoing Phase 1/2 trial of petosemtamab monotherapy in previously treated (2L+) recurrent/metastatic head and neck squamous cell carcinoma (r/m HNSCC). The data, with a July 5, 2024 cutoff, was presented at the European Society for Medical Oncology (ESMO®) Asia Congress.
The results demonstrated clinically meaningful activity for petosemtamab monotherapy in this patient population. The durability of the monotherapy treatment compares favorably to current standard of care, indicating a positive outlook for the ongoing Phase 3 investigation.
These findings reinforce the potential of petosemtamab to become a new standard of care for patients with r/m HNSCC, a disease with limited treatment options. The data supports the continued advancement of Merus's lead wholly-owned candidate.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.